FDMT
insider transactions4D Molecular Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-2.3K
0 buy · 2.3K sell
Net value · 365d
-$22.6K
$0 in · $22.6K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
3
0 buy · 2.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
75.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Sell·S
David Kirn KEY
President and Chief Executive… · 10b5-1
$19.3K
1.9K sh · $10.02
Own -0%
-
Grant·A
David Kirn KEY
Chief Executive Officer
$0
750.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
217.0K sh
Own New
-
Grant·A
Chief Commercial and Business…
$0
219.0K sh
Own New
-
Exercise·M
VP, Finance and Controller
$0
221 sh
Own +8%
-
Exercise·M
VP, Finance and Controller
$0
865 sh
Own +8%
-
Sell·S
VP, Finance and Controller
$689
80 sh · $8.61
Own -0%
-
Exercise·M
VP, Finance and Controller
—
221 sh
Own +0%
-
Sell·S
VP, Finance and Controller
$2.7K
310 sh · $8.61
Own -1%
-
Exercise·M
VP, Finance and Controller
—
865 sh
Own +2%
-
Grant·A
Director
$0
45.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Shawn Tomasello | Grant A | 50.0K | $0 |
| Jun 17, 2026 | Charles Theuer | Grant A | 50.0K | $0 |
| Jun 17, 2026 | Nancy Miller-Rich | Grant A | 50.0K | $0 |
| Jun 17, 2026 | Susannah Gray | Grant A | 50.0K | $0 |
| Jun 17, 2026 | John F Milligan | Grant A | 75.0K | $0 |
| Jun 17, 2026 | Glenn Sblendorio | Grant A | 50.0K | $0 |
| Jun 17, 2026 | Jacob Chacko | Grant A | 50.0K | $0 |
| Jun 1, 2026 | David Kirn KEY 10b5-1 | Sell S | 1.9K | $19.3K |
| Mar 25, 2026 | David Kirn KEY | Grant A | 750.0K | $0 |
| Mar 25, 2026 | Scott Bizily | Grant A | 217.0K | $0 |
| Mar 25, 2026 | Christopher Paul Simms | Grant A | 219.0K | $0 |
| Mar 20, 2026 | Ashoo Gupta | Exercise M | 221 | $0 |
| Mar 20, 2026 | Ashoo Gupta | Exercise M | 865 | $0 |
| Mar 20, 2026 | Ashoo Gupta | Sell S | 80 | $689 |
| Mar 20, 2026 | Ashoo Gupta | Exercise M | 221 | — |
| Mar 20, 2026 | Ashoo Gupta | Sell S | 310 | $2.7K |
| Mar 20, 2026 | Ashoo Gupta | Exercise M | 865 | — |
| Jan 5, 2026 | Glenn Sblendorio | Grant A | 45.0K | $0 |
About FDMT insider trading
This page tracks insider transactions for 4D Molecular Therapeutics, Inc. (FDMT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.